Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fentanyl, quantity: 7.65 mg - drug delivery system, transdermal - excipient ingredients: dimeticone 360; methylated trimethylated silica; heptane; polyethylene terephthalate; polyvinylidene flouride; ethyl acetate; polyisocyanate; 4,4'-diphenylmethane diisocyanate; silane; polyethylene; titanium dioxide; polypropylene; ethylene/propylene copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate; tris(2,4-ditert-butyphenyl) phosphite; calcium stearate; aluminium magnesium hydroxide carbonate; perflouropropylene/vinylidene diflouride copolymer; 1,3,5-trimethyl-2,4,6-tris(3,5-ditert-butyl-4-hydroxybenzyl)benzene; aluminium calcium sodium silicate; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; iron oxide red; pigment yellow 119; zinc stearate; potable water; trolamine; strong ammonia solution; industrial methylated spirit; styrene/acrylates copolymer; polytef; dimeticone 350; docusate sodium; propylene glycol; purified water; acrylates copolymer; methoxyisopropyl acetate; 2-ethylhexyl acrylate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fentanyl, quantity: 5.1 mg - drug delivery system, transdermal - excipient ingredients: dimeticone 360; methylated trimethylated silica; heptane; polyethylene terephthalate; polyvinylidene flouride; titanium dioxide; potable water; trolamine; strong ammonia solution; industrial methylated spirit; styrene/acrylates copolymer; polyethylene; polytef; dimeticone 350; docusate sodium; propylene glycol; purified water; acrylates copolymer; methoxyisopropyl acetate; 2-ethylhexyl acrylate; ethyl acetate; polyisocyanate; 4,4'-diphenylmethane diisocyanate; silane; polypropylene; ethylene/propylene copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate; tris(2,4-ditert-butyphenyl) phosphite; calcium stearate; aluminium magnesium hydroxide carbonate; perflouropropylene/vinylidene diflouride copolymer; 1,3,5-trimethyl-2,4,6-tris(3,5-ditert-butyl-4-hydroxybenzyl)benzene; aluminium calcium sodium silicate; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; iron oxide red; pigment yellow 119; zinc stearate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

leo pharma pty ltd - methylprednisolone aceponate, quantity: 1 mg/g - ointment - excipient ingredients: white soft paraffin; liquid paraffin; white beeswax; purified water; dicocoyl pentaerythrityl distearyl citrate; sorbitan sesquioleate; aluminium stearate - topical treatment of eczema and psoriasis. indications as at 7 december 2001. topical eczema and psoriasis.

Australia - English - Department of Health (Therapeutic Goods Administration)

ac newco pty ltd - octocrylene, quantity: 85 mg/g; homosalate, quantity: 80 mg/g; bemotrizinol, quantity: 60 mg/g; butyl methoxydibenzoylmethane, quantity: 40 mg/g; titanium dioxide, quantity: 29.6 mg/g; methylene bis-benzotriazolyl tetramethylbutylphenol, quantity: 25 mg/g; polysilicone-15, quantity: 20 mg/g - cream - excipient ingredients: purified water; cyclomethicone; dibutyl adipate; ethanol; peg-30 dipolyhydroxystearate; styrene/acrylates copolymer; peg-12 dimeticone/ppg-20 crosspolymer; acrylates/acrylamide copolymer; bis-ethylhexyl hydroxydimethoxy benzylmalonate; phenoxyethanol; jojoba esters; iron oxide yellow; hexyl laurate; polyglyceryl-4 isostearate; sodium chloride; pvp/hexadecene copolymer; decyl glucoside; sunflower seed; disteardimonium hectorite; cetyl dimeticone; dimeticone 350; disodium edetate; ethylhexylglycerin; carnauba wax; polyglyceryl-3 diisostearate; hydrogenated lecithin; propylene glycol; xanthan gum; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate; iron oxide red; iron oxide black; silicon dioxide; fragrance (perfume) - may assist in preventing some skin cancers (sunscreen) ; may reduce the risk of some skin cancers (sunscreen) ; spf 50 plus broad spectrum very high protection sunscreen ; can aid in the prevention of premature skin ageing (sunscreen) ; can aid in the prevention of solar keratosis (sunscreen) ; can aid in the prevention of sunspots (sunscreen)

Australia - English - Department of Health (Therapeutic Goods Administration)

ac newco pty ltd - octocrylene, quantity: 100 mg/g; butyl methoxydibenzoylmethane, quantity: 45 mg/g; homosalate, quantity: 100 mg/g; diethylamino hydroxybenzoyl hexyl benzoate, quantity: 70 mg/g; octyl salicylate, quantity: 50 mg/g; polysilicone-15, quantity: 20 mg/g; ethylhexyl triazone, quantity: 50 mg/g - gel - excipient ingredients: bis-ethylhexyl hydroxydimethoxy benzylmalonate; sunflower seed; d-alpha-tocopheryl acetate; cyclomethicone; coco-octanoate/decanoate; isohexadecane; alkyl (c12-15) benzoate; silica dimethyl silylate; dipropylene glycol dibenzoate; acrylates/acrylamide copolymer; pvp/hexadecene copolymer; ppg-15 stearyl ether benzoate; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate; d-alpha-tocopherol; salvia hispanica; zingiber officinale; fragrance (perfume) - may assist in preventing some skin cancers (sunscreen) ; may reduce the risk of some skin cancers (sunscreen) ; spf 50 plus broad spectrum very high protection sunscreen ; can aid in the prevention of premature skin ageing (sunscreen) ; can aid in the prevention of solar keratosis (sunscreen) ; can aid in the prevention of sunspots (sunscreen)

Australia - English - Department of Health (Therapeutic Goods Administration)

l'oreal australia pty ltd - butyl methoxydibenzoylmethane, quantity: 40 mg/g; octocrylene, quantity: 35 mg/g; octyl salicylate, quantity: 50 mg/g; homosalate, quantity: 50 mg/g; bemotrizinol, quantity: 15 mg/g; ethylhexyl triazone, quantity: 25 mg/g; drometrizole trisiloxane, quantity: 10 mg/g; ecamsule, quantity: 3.3 mg/g - spray - excipient ingredients: caprylyl glycol; diisopropyl sebacate; dimeticone 5; ethylenediamine/stearyl dimer dilinoleate copolymer; diglycol/chdm/isophthalates/sip copolymer; peg-8 laurate; trolamine; ethanol; dicaprylyl carbonate; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate; purified water; acrylates copolymer; glycerol; styrene/acrylates copolymer; disodium edetate; dl-alpha-tocopherol; fragrance (perfume) - may assist in preventing some skin cancers (sunscreen) ; may reduce the risk of some skin cancers (sunscreen) ; spf 50 plus broad spectrum very high protection sunscreen ; can aid in the prevention of premature skin ageing (sunscreen) ; can aid in the prevention of solar keratosis (sunscreen) ; can aid in the prevention of sunspots (sunscreen)

Ireland - English - HPRA (Health Products Regulatory Authority)

leo pharma a/s - methylprednisolone aceponate - ointment - 0.1 percent weight/weight - methylprednisolone aceponate

Ireland - English - HPRA (Health Products Regulatory Authority)

leo pharma a/s - methylprednisolone aceponate - cream - 0.1 percent weight/weight - methylprednisolone aceponate

European Union - English - EMA (European Medicines Agency)

plethora pharma solutions limited - lidocaine, prilocaine - premature ejaculation - anesthetics - senstend is indicated for the treatment of primary premature ejaculation in adult men.

United Kingdom - English - VMD (Veterinary Medicines Directorate)

laboratorios calier, sa - amitraz - bee-hive strip - ectoparasiticide - honey bees